osimertinib resistance

Ask MedXY AI

Latest news

Tag

newsEGFR mutationNSCLC

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY|Oct 25, 2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

Clinical UpdatesEGFR-mutated NSCLCMET amplification

Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study

By MedXY|Oct 2, 2025

Savolitinib plus osimertinib showed clinically meaningful responses in patients with EGFR-mutated advanced NSCLC and high MET overexpression/amplification after progression on first-line osimertinib, offering a new targeted therapy option.